...prostate cancer and non-Hodgkin lymphoma (Yang et al. 2012, Jie et al. 2013, Yan et al. 2013, Cheng et al. 2015, Japp et al. 2015, Ji et al. 2015, Thommen et al. 2015, Cai et al. 2016, Xie et al. 2016). Preclinical models show conflicting results for the administration of TIM3-targeting monoclonal a ~~~

...prostate cancer immunotherapy 10.1530/ERC-17-0145 Melissa Gamat and Douglas G McNeel University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA Abstract Prostate cancer is the most common newly diagnosed malignancy in men, and the second most common cause of cancer-related death in the U ~~~

...prostate peptide vaccines The MKC1106-PP vaccine consists of a DNA vector, pPRA-PSM, encoding segments of two tumor antigens, PRAME and PSMA (Weber  et  al. 2011). Both PRAME and PSMA are expressed in a range of tumours (Silver  et  al. 1997, Conway et al. 2006, Lerut et al. 2015). The former facili ~~~

...prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, T344Thematic Review P Cukier et al. Immunotherapy-induced endocrinopathies DOI: 10.1530/ERC-17-0358 http://.endocrinology-journals.org © 2018 Society for Endocrinology Printed in Great Britain Published by B ~~~

...prostate cancers (Kantoff et al. 2010). The field of DC vaccination is in its infancy, but this complex therapeutic strategy is being refined and improved each year (Butterfield 2013). Cost will continue to be a caveat for DC vaccines for the foreseeable future, but should not hinder the pursuit of ~~~